RT Journal Article SR Electronic T1 A cohort study to evaluate the effect of combination Vitamin D, Magnesium and Vitamin B12 (DMB) on progression to severe outcome in older COVID-19 patients JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.06.01.20112334 DO 10.1101/2020.06.01.20112334 A1 Tan, Chuen Wen A1 Ho, Liam Pock A1 Kalimuddin, Shirin A1 Cherng, Benjamin Pei Zhi A1 Teh, Yii Ean A1 Thien, Siew Yee A1 Wong, Hei Man A1 Tern, Paul Jie Wen A1 Chandran, Manju A1 Chay, Jason Wai Mun A1 Nagarajan, Chandramouli A1 Sultana, Rehena A1 Low, Jenny Guek Hong A1 Ng, Heng Joo YR 2020 UL http://medrxiv.org/content/early/2020/06/10/2020.06.01.20112334.abstract AB Objective To determine the clinical outcomes of older COVID-19 patients who received DMB compared to those who did not. We hypothesized that fewer patients administered DMB would require oxygen therapy and/or intensive care support than those who did not.Methodology Cohort observational study of all consecutive hospitalized COVID-19 patients aged 50 and above in a tertiary academic hospital who received DMB compared to a recent cohort who did not. Patients were administered oral vitamin D3 1000 IU OD, magnesium 150mg OD and vitamin B12 500mcg OD (DMB) upon admission if they did not require oxygen therapy. Primary outcome was deterioration post-DMB administration leading to any form of oxygen therapy and/or intensive care support.Results Between 15 January and 15 April 2020, 43 consecutive COVID-19 patients aged ≥50 were identified. 17 patients received DMB and 26 patients did not. Baseline demographic characteristics between the two groups was significantly different in age. In univariate analysis, age and hypertension showed significant influence on outcome while DMB retained protective significance after adjusting for age or hypertension separately in multivariate analysis. Fewer DMB patients than controls required initiation of oxygen therapy during their hospitalization (17.6% vs 61.5%, P=0.006). DMB exposure was associated with odds ratios of 0.13 (95% CI: 0.03 – 0.59) and 0.20 (95% CI: 0.04 – 0.93) for oxygen therapy and/or intensive care support on univariate and multivariate analyses respectively.Conclusions DMB combination in older COVID-19 patients was associated with a significant reduction in proportion of patients with clinical deterioration requiring oxygen support and/or intensive care support. This study supports further larger randomized control trials to ascertain the full benefit of DMB in ameliorating COVID-19 severity.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIt is registered under ISRCTN15324611Funding StatementNot a funded study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by our institutional ethics committee with waiver of consent granted (Ref No:2020/2344).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data for this manuscript is available from the corresponding author.